Nucleoside analogs with 2 0 -modified sugar moieties are often used to improve the RNA target affinity and nuclease resistance of therapeutic oligonucleotides in preclinical and clinical development. Despite their enhanced nuclease resistance, oligonucleotides could slowly degrade releasing nucleoside analogs that have the potential to become phosphorylated and incorporated into cellular DNA and RNA. For the first time, the phosphorylation and DNA/RNA incorporation of 2 0 -O-(2-methoxyethyl) (2 0 -O-MOE) nucleoside analogs have been investigated. Using liquid chromatography/tandem mass spectrometry, we showed that enzymes in the nucleotide salvage pathway including deoxycytidine kinase (dCK) and thymidine kinase (TK1) displayed poor reactivity toward 2 0 -O-MOE nucleoside analogs. On the other hand, 2 0 -fluoro (F) nucleosides, regardless of the nucleobase, were efficiently phosphorylated to their monophosphate forms by dCK and TK1. Consistent with their efficient phosphorylation by dCK and TK1, 2 0 -F nucleoside analogs were incorporated into cellular DNA and RNA while no incorporation was detected with 2 0 -O-MOE nucleoside analogs. In conclusion, these data suggest that the inability of dCK and TK1 to create the monophosphates of 2 0 -O-MOE nucleoside analogs reduces the risk of their incorporation into cellular DNA and RNA.
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Oligonucleotide-based therapeutics have the potential to modulate gene expression in mammalian cells to treat a wide range of diseases including cancer, inflammatory, dyslipidemia, and infectious diseases (Kole and Leppert, 2012; Shahbazi et al., 2016) . Various chemical modifications to the base, sugar, and backbone have been developed and applied to therapeutic oligonucleotides to improve their pharmacokinetics and pharmacodynamics properties (Deleavey and Damha, 2012) . One of the most widely used modifications for antisense oligonucleotides is phosphorothioate internucleotide linkages whereby one of the nonbridging oxygen atoms in the phosphodiester linkage is replaced by sulfur (Eckstein, 2000) . These first-generation phosphorothioate oligonucleotides (PS ODN) have sufficient nuclease resistance, support RNase H activity, and bind plasma proteins which is critical to maintain favorable pharmacokinetics and tissue distribution properties (Eckstein, 2000) . Subsequently, the so-called second generation of chemical modifications were developed by modifying the 2 0 -position of the sugar moiety of the ODN with either an alkyl group (eg, 2 0 -O-methyl, or 2 0 -O-methoxyethyl) or a 2 0 -fluoro group (Monia, 1997) . These modifications increased the hybridization affinity by holding the ribose ring in a configuration that is optimal for hydrogen bonding with the target RNA strand . The 2'-F modification has been used extensively in siRNA constructs, whereas the single-stranded phosphorothioate ODNs more commonly use the 2 0 -alkyl modifications. The second generation chemistry that is most well studied in development is the 2 0 -O-MOE modified PS ODN (Geary et al., 2001a) . The 2 0 -alkyl modifications have an added benefit in that they further enhance nuclease resistance and modulate the pharmacokinetic properties of antisense ODNs (Prakash, 2011) . As fully 2 0 -ribose modified oligonucleotides do not support RNase H to cleave the target RNA, so-called gapmers were developed whereby the ribose sugar modifications are confined to both ends of ODN leaving a central "gap" of unmodified 2 0 -deoxyphosphorothioate nucleotides (Monia et al., 1993) . For example, the FDA-approved antisense drug "Mipomersen", used to treat familial hypercholesterolemia, is a 20-mer fully phosphorothioated oligo with 2 0 -O-MOE modified ribose at both ends (Crooke and Geary, 2013) . This makes the 3 0 -and 5 0 -end of the antisense oligonucleotide highly resistant to exonucleasemediated metabolism.
The genotoxic potential for single-stranded PS ODN has been thoroughly examined, with and without 2 0 -alkyl modifications, and have been found to be uniformly absent of any genotoxicity potential, but the implications of the liberated mononucleotides have never been directly assessed (Berman et al., 2016; Henry et al., 2002) . The released nucleotide analog could have a genotoxic potential either via perturbation of the endogenous nucleotide pool or by incorporation into newly synthesised genomic DNA potentially leading to mutation or chromosome breakage (Mattano et al., 1990; Phear et al., 1987) . The likelihood of unbalancing nucleotide pools through slow nuclease mediated metabolism seems an unlikely concern because this would be addressed by the standard genotoxicity assays where uptake and metabolism at extraordinarily high concentrations have been documented without genotoxic impact (Henry et al., 2002) . However, the European Medicines Agency (EMA) raised a concern on the genotoxic potential of the liberated nucleotide analogs as they could serve as substrates for various intracellular kinases which would represent the first crucial step for their incorporation into newly synthesised DNA http://www. ema.europa.eu/docs/en_GB/document_library/Scientific_guide-line/2009/09/WC500003149.pdf, last accessed January 12, 2018. Indeed, using in vitro polymerase extension assays, previous studies showed that 2 0 -fluorodeoxynucleotides were substrates for human DNA polymerases including polymerase alpha (pol a) and polymerase gamma (pol c), and could be incorporated into primed DNA (Richardson et al., 2000) . Subsequently, the same group demonstrated that 2 0 -fluoropyrimidines (2 0 -F-C and 2 0 -F-U) could be incorporated into DNA and RNA of various tissues of rats and woodchucks following long-term treatment (90 days) (Richardson et al., 2002) . These studies raise a question as to whether other commonly employed 2 0 -ribose modifica- Enzymatic reaction. The phosphorylation reactivity of modified nucleosides by dCK was analyzed by incubating 200mM of the indicated nucleoside in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl 2 , 1 mM ATP and 1 mg of enzyme in a 50 ml reaction volume at 37 C for 2 h. Phosphorylation by TK1 was analyzed in 50 mM Tris-HCl pH 7.5, 2.5 mM MgCl 2 , 10 mM dithiotreitol (DTT) and 3 mM NaF. AK1 and GK1 were assayed with 1 mg of the respective enzyme, 1 mM ATP and 200 mM of substrate in 100 mM Tris-HCl (pH 7.8), 100 mM KCl and 10 mM MgCl 2 . CMPK was assayed as above but in 100 mM Tris-HCl (pH 9), 250 mM KCl, 15 mM Mg-acetate and 5 mM DTT. DTYMK was assayed as above but in 50 mM Tris-HCl pH 7.5, 2.5 mM MgCl2, 10 mM DTT, and 3 mM NaF.
Nucleotide pool, RNA, and genomic DNA extraction. TK6 cells (4 Â 10 5 cell/ml) seeded in a 24-well plate were treated with the indicated concentration of the nucleotide for 24 h. Cells were treated with 100 mM of isotope-labeled cytidine ( 15 N 3 ) for 4 h before nucleic acid extraction. To remove extracellular nucleosides for the analysis of intracellular exposure of modified nucleosides, cells were first pelleted by centrifugation for 5 min at 300 Â g in a 1.5 ml microcentrifuge tube. The supernatant was completely removed and the cell pellet was suspended in 1 ml of ice-cold PBS by gentle vortexing. The cell suspension was then centrifuged for 5 min at 300 Â g before removing the PBS solution, and the washing step was repeated twice. The intracellular nucleotide pool was extracted by adding 1 ml of ice-cold 80% methanol to the cell pellet. The samples were then vortexed, centrifuged for 10 min at 20 000 Â g and the supernatant was transferred to a new microfuge tube and dried by SpeedVac at 37 C for 1.5 h.
The samples were then diluted in 50 ml of H 2 O. For DNA and RNA extraction, the cells were washed 3 times with PBS. DNA was then extracted using the DNeasy Kit (Qiagen) according to the manufacturer protocol. In brief, the cell pellet was suspended in 200 ml of PBS before the addition of 20 ml of Proteinase K, 4 ml of RNase A (100 mg/ml) and 200 ml of lysis buffer provided with the kit. The samples were then mixed by vortexing and incubated at 56 C for 10 min and 200 ml ethanol (>99.6%) added to the sample and mixed by vortexing. The mixture was then pipetted into DNeasy Mini spin column (provided with the kit) and centrifuged at 6000 Â g for 1 min during which the DNA is bound to the DNeasy membrane. This is followed by 2 wash steps to remove contaminants. The DNA in the spin column was washed with 500 ml of ethanol-based wash buffer (provided with the kit) and centrifuged for 1 min at 6000 Â g. The spin column was placed in a new collection tube and washed with 500 ml of ethanol-based wash buffer (provided with the kit) and centrifuged for 3 min at 20 000 Â g. DNA was then eluted by pipetting 200 ml buffer EB onto the DNeasy membrane and incubation at room temperature for 1 min before centrifugation for 1 min at 6000 Â g. Total RNA (longer than 200 nucleotides) was extracted and purified using RNeasy Mini kit (Qiagen) according to the manufacturer protocol. In brief, the cell pellet was suspended in 350 ml of lysis buffer (provided with the kit) followed by vortexing. The Lysate was pipetted into QIAshredder spin column and centrifuged for 2 min at 20 800 Â g. One volume of 70% ethanol was added to the homogenized lysate and mixed well by pipetting. The mixture was then transferred to an RNeasy spin column and centrifuged for 15 s at 8000 Â g. The column was washed with 350 ml wash buffer (provided with the kit) and centrifuged for 15 s at 8000 Â g. DNase (10 ml) was added to the spin column and incubated at toom temperature for 15 min followed by the addition of 350 ml wash buffer (provided with the kit). Columns were then centrifuged for 15 s at 8000 Â g and washed twice with 500 ml ethanol-based wash buffer (provided with the kit). RNA was eluted by addition of 50 ml RNasefree water followed by centrifugation for 1 min at 8000 Â g. DNA and RNA and nucleotide pool extract were hydrolyzed as described before in Bachman et al. (2014) . In brief, DNA or RNA (1-2 mg) was incubated with 5 U of DNA Degradase Plus (Zymo Research) in a total volume of 50 ml for 3 h at 37 C.
Liquid chromatography/tandem mass spectrometry analysis. Analysis was performed on Acquity UPLC I-class system. The mobile phase solvent A consisted of HPLC graded water containing 0.1% formic acid, and solvent B consisted of acetonitrile containing 0.1% formic acid. Analysis was performed using a mobile phase flow rate of 0.6 ml/min using a linear gradient starting from 2% solvent B to 98% solvent B in 3.5 min and equilibrated at 2% solvent B for 1 min and a Waters XSelect HSS T3, 3.5 mm HPLC column (2.1 Â 50 mm) (Waters). Samples were analyzed on atmospheric pressure ionization (API) 4000 triple quadrupole mass spectrometer (Applied Biosystems, CA). Nucleosides were monitored in the selected reaction monitoring (SRM) mode using positive ion API at a source temperature of 450 C and an IonSpray voltage of 4200 V and a collision en- Statistical analysis. The data were tested for statistical significant differences with 1-way ANOVA.
RESULTS
Phosphorylation of 2 0 -O-MOE and 2 0 -F Nucleosides
To be utilized by cellular DNA polymerases for DNA incorporation, nucleoside analogs must be converted to their active triphosphate form via sequential phosphorylation by various kinases in the nucleotide salvage pathway. Therefore, we first examined the ability of salvage enzyme activity to convert of 2 0 -O-MOE nucleosides to their monophosphate forms by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Calibration curves, correlation coefficient (r 2 ), retention times and limit of detection (LOD) are shown in Supplementary Figure  1 . We examined the substrate activity of the 2 main salvage enzymes, human dCK and TK1, on 2 0 -O-MOE nucleoside analogs. We have chosen dCK and TK1 as both are located in the cytosol and can phosphorylate natural purine and pyrimidine deoxyribonucleosides (Johansson and Eriksson, 1996) . In addition, comparisons were made with 2 0 -F nucleosides widely used in siRNA therapeutics (Watts et al., 2008) . To the best of our knowledge, there are no reports on the substrate activity of human dCK and TK1 towards 2 0 -F nucleosides except 2 0 -F-C (Kierdaszuk et al., 1999) . Structures of 2 0 -O-MOE and 2 0 -F nucleosides are shown in Figure 1A . The level of conversion was calculated based on relative peak area ratios of the reactant before and after the kinase reaction ( Supplementary Figure 2 for extracted ion chromatograms). As shown in Figure 1B , dCK displayed poor reactivity towards 2 0 -O-MOE purine nucleosides and was only able to convert about 5% of 2 0 -O-MOE-G to monophosphate and was not able to convert 2 0 -O-MOE-A at all.
Similarly, 2 0 -O-MOE-5meC and 2 0 -O-MOE-T were poor substrates for dCK and TK1 phosphorylating 5% of 2 0 -O-MOE-5mC and 4% of 2 0 -O-MOE-T, respectively ( Figure 1B ). In contrast, 2 0 -F nucleosides were remarkably good substrates for both dCK and TK1, regardless of the nucleobase, exhibiting similar substrate activities (>95% conversion) to their respective natural 2 0 -deoxy nucleosides ( Figure 1B) . We next examined the capacity of human nucleoside monophosphate kinases including CMPK1, DTYMPK, AK1 and GK1 to phosphorylate 2
O-MOE-G monophosphates respectively. As shown in Figure 1C , AK1, GK1, CMPK1, and dTMPK were not able to create diphosphates of 2 0 -O-MOE modified nucleoside monophosphates regardless of the nitrogenous base. In contrast, AK1 and GK1 were able to phosphorylate (about 95% conversion) dAMP and dGMP controls, respectively. Similarly, CMPK1 and DTMK were able to phosphorylate >70% of CMP and TMP, respectively ( Figure 1C ). Extracted ion chromatograms are shown in Supplementary  Figure 3 .
Cellular DNA and RNA Incorporation of 2 0 -O-MOE Nucleosides
The final substrate required by DNA and RNA polymerases for nucleoside incorporation into DNA and RNA is the nucleoside triphosphate. Therefore, the minimal activity of nucleoside kinases and nucleoside monophosphate kinases on 2 0 -O-MOE nucleoside analogs is likely to present a major barrier for their incorporation into cellular DNA and RNA. To confirm this, we asked whether the treatment with 2 0 -O-MOE-or 2 0 -F-modified nucleosides leads to their DNA and RNA incorporation in TK6 human lymphoblastoid cells. We used TK6 cells as they are human-derived and widely used for genotoxicity testing including the in vitro micronucleus assay and gene mutation assays (Lorge et al., 2016) . It is important to add that TK6 cells are p53-competent and therefore mount a robust DNA damage response. In addition, the growth characteristics of TK6 cells and their identity (karyotypes and genetic status) are wellcharacterised. Accordingly, we incubated TK6 cells with different concentrations (10, 250, and 1000 mM) of 2 0 -O-MOE nucleosides or their monophosphate forms for 24 hr. Comparisons were made to 2'-F nucleosides as previous results showed that 2'-F pyrimidines can be incorporated into cellular DNA and RNA (Richardson et al., 2002) . Following treatment, DNA and RNA were extracted and digested to nucleosides and analyzed by LC/ MS/MS as described under the "Materials and Methods" section. Figure 2A ). For example, treatment with 250 and 1000 mM of 2 0 -F-A resulted in 50% and 92% reduction DNA synthesis compared with control, respectively. When cells were treated with 1000 mM of 2 0 -F-G and 2 0 -F-C, a sharp decrease ( $ 65% to 90%) in DNA synthesis compared with control was observed (Figure 2A) . Likewise, treatment with all 2 0 -F nucleoside analogous resulted in a concentration dependent decrease in RNA synthesis ( Figure 2B ). Figure 3A . Figure 3B shows examples of extracted ion chromatograms derived from hydrolyzed DNA and RNA from cells treated with 250 mM of 2 0 -O-MOE-G and 2 0 -F-G nucleosides. Treating TK6 cells for 24 h with 2 0 -O-MOE nucleosides or their monophosphates, regardless of the nucleobase, did not result in DNA or RNA incorporation using various concentrations up to 1000 mM. On the other hand, when cells were exposed to 2 0 -F nucleosides, we were able to detect incorporation of all nucleosides into DNA except 2 0 -F-U. For example, after treatment with 2 0 -F-G (250 mM), 12% of total dG contained 2'-F-G modifications ( Figure 3C ). As might be expected even higher levels of incorporation of 2'-F nucleosides were seen for RNA. For example, 2'-F-C nucleosides accounted for as much as 46% of total cytidine content after treatment with 1000 mM of 2'-F-C nucleosides ( Figure 3C ). It should be noted that when we analyzed undigested DNA or RNA samples, we did not observe a detectable signal for any of the natural or modified nucleosides suggesting efficient removal of extracellular nonincorporated nucleosides from the DNA or RNA samples before hydrolysis.
Intracellular Exposure of 2 0 -O-MOE Nucleosides and Their
Monophosphates To become incorporated into cellular DNA and RNA, nucleoside analogs must display efficient uptake across the plasma membrane. It is possible that the lack of 2 0 -O-MOE nucleosides incorporation into cellular DNA and RNA was due to poor cellular uptake. Therefore, we determined the intracellular exposure of modified nucleotides by measuring the ratio of the signal from the indicated nucleoside to endogenous nucleosides in the nucleotide pool extracts. Incubation of TK6 cells with various concentrations (10, 250, and 1000 mM) of 2 0 -O-MOE for 24 h resulted in a significant intracellular uptake that was concentrationdependent ( Figure 4 ). However, 2 0 -O-MOE-A and 2 0 -O-MOE-G showed significantly lower cellular uptake than 2 0 -O-MOE-5mC or 2 0 -O-MOE-T (Figure 4) , the latter of which accumulated to higher concentrations than their native nucleoside counterparts. In general, the cellular uptake of 2 0 -O-MOE nucleoside monophosphates was lower than their respective nucleosides. Nonetheless, we were able to demonstrate intracellular uptake of 2 0 -O-MOE nucleoside monophosphates that was concentration dependent (Figure 4) . Similarly, treating TK6 cells with 2'-F nucleosides resulted in a concentration dependent increases in the cellular uptake up to 1000 mM with lower accumulation of 2'-F-A, -G, and -U than 2'-F-C.
DISCUSSION
In this study, we demonstrated that 2 0 -O-MOE nucleosides are neither effectively phosphorylated by cytosolic nucleoside kinases, nor are they incorporated into cellular DNA or RNA. In contrast, 2 0 -F modified nucleosides are readily phosphorylated and under our experimental conditions are incorporated at relatively high levels into cellular DNA and RNA, which in turn is accompanied by reductions in DNA and RNA synthesis. To the best of our knowledge, this is the first report evaluating the phosphorylation and DNA/RNA incorporation of 2 0 -O-MOE nucleoside analogs and provides confidence in the safe application, with regard to liberated nucleosides, of oligonucleotide therapeutics containing this modification. Much of the understanding of nucleoside salvage pathways comes from the area of nucleoside analogs used as antiviral and oncology drugs aimed at inhibiting DNA synthesis and RNA transcription (Sofia, 2011; Van Rompay et al., 2000) . These drugs are often given as prodrugs that require phosphorylation by endogenous kinases to their triphosphate forms to become incorporated into viral or cellular DNA. In general, the formation of the monophosphate is the rate-limiting step in the activation of nucleoside drugs.
Our data suggests that the limited activity of nucleoside salvage kinases towards 2 0 -O-MOE nucleosides represents a major barrier for their cellular DNA and RNA incorporation. The absence of DNA and RNA incorporation of 2 0 -O-MOE nucleosides is unlikely to be due to the lack of cell exposure or inhibition of DNA and RNA synthesis as we were able to detect 2 0 -O-MOE nucleosides in the intracellular nucleotide pool and 2 0 -O-MOE treatments even at the highest concentrations used (1000 mM) had minimal effect on DNA and RNA synthesis. In addition, the LC/MS/MS assay described in this paper to detect 2 0 -O-MOE and their respective native nucleosides has a LOD in the femtomole range which is in line with previous reports (Bachman et al., 2014) . With the exception of 2 0 -F-U, all 2 0 -F nucleoside analogs were incorporated into cellular DNA and RNA indirectly suggesting that 2 0 -F nucleosides were phosphorylated to their respective 5 0 -triphosphates and incorporated by cellular DNA and RNA polymerases. This is consistent with previous reports showing that human cellular polymerases (pol a and pol c) could incorporate 2 0 -F nucleosides into primed DNA in vitro (Richardson et al., 2000) . Later work from the same lab demonstrated incorporation of 2 0 -F-C and 2 0 -F-U into DNA and RNA of various tissues of rats and woodchucks following long-term in vivo treatment (Richardson et al., 2002) . Although showing almost complete phosphorylation by TK1, in our hands, 2 0 -F-U nucleosides were not incorporated into cellular DNA and RNA. One potential reason for this lack of incorporation could lie in the limited intracellular exposure observed with the 2'-F-U nucleosides (Figure 4) . Also, the calibrated sensitivity of our LC/MS/MS methodology for detection of 2'-F-U was lower than experiments are indicated. **p < .01, ***p < .001, and ****p < .0001. ns, not significant.
for the other modified nucleosides (Supplementary Figure 1) , therefore incorporation might have been below our detectable limits. Indeed, the LC/MS/MS assay used by Richardson et al. (2002) was able to detect 2 0 -F-U as low as 400 pM while the limit of 2 0 -F-U detection described herein is 10 nM. In addition, it is possible that the difference in 2 0 -F-U incorporation into DNA/RNA in vivo and the lack of incorporation in vitro as described in this article was due to variations in the cellular uptake or the phosphorylation capacity of salvage enzymes. Variations in the phosphorylation and anti-influenza activity of 2 0 -F nucleosides in different cell lines was previously reported (Tisdale et al., 1993) , thus it is possible that certain phosphorylating enzymes of the nucleotide salvage pathway are absent or expressed differently in TK6 cells, potentially inhibiting the incorporation of 2'-F-U into cellular DNA/RNA. In contrast to 2 0 -O-MOE nucleosides, 2 0 -F nucleosides treatment resulted in concentration dependent inhibition of DNA synthesis which was evident with 2 0 -F-A, 2 0 -F-G and 2 0 -F-C.
Several previous studies showed that 2 0 -F-C inhibits cell growth and induces cytostasis due to an S-phase arrest (Brox et al., 1974; Stuyver et al., 2004) . Similarly, data presented here showed that 2 0 -F-C reduced DNA synthesis by about 30% at 250 mM ( Figure 2A ). This inhibitory effect on cell growth could be promoted by genomic DNA incorporation potentially leading to double strand DNA breaks (Shen et al., 2015) . Yet, we cannot exclude other mechanisms of toxicity including disruption of the endogenous nucleotide pool balance or disruption of mitochondrial DNA synthesis (Kunz et al., 1994; Pan-Zhou et al., 2000) . Further studies are needed to understand the underlying mechanisms responsible for this activity of the 2 0 -F nucleosides.
However, taken together, these data suggest that caution should be applied when considering the use and application of 2 0 -F modifications in therapeutic oligonucleotides.
Although nonnatural 2 0 -sugar modifications of therapeutic oligonucleotides can enhance target binding affinity and nuclease stability, the potential of 2 0 -nucleosides analogs to become incorporated into genomic DNA potentially leading to DNA replication errors or mutations raises a safety concern for therapeutic oligonucleotides. In general, 2 0 -F nucleoside analogs are commonly used in siRNA-based therapeutics to increase binding affinity and reduce immune activation (Watts et al., 2008) . However, only a limited number of nuclease resistant phosphorothioate linkages can be tolerated while still providing siRNA efficacy. Moreover, while 2 0 -F modification confers increased hybridization affinity, it does not confer nuclease resistance (Manoharan, 1999) . These 2 factors are likely to increase the potential of 2 0 -F catabolism and nucleoside release and therefore subsequent conversion by cellular kinases to their triphosphate forms for incorporation into newly synthesised DNA. This could have genotoxic consequences as 2 0 -F sugar modifications have been demonstrated to destabilize B-DNA duplex by inducing a more A-like conformation (Ikeda et al., 1998) . Furthermore, once incorporated into DNA, 2 0 -F nucleosides appear resistant to normal mechanism of DNA repair as a fluorine at C2 0 blocks the activity of glycosylases, thus inhibiting base excision repair for these analogs Su et al., 2016) . Notwithstanding these considerations, chronic safety studies in rats and woodchucks have shown that despite 2 0 -F-U and 2 0 -F-C incorporation into tissue DNA and RNA, there are minimal toxicological consequences of the incorporation (Richardson et al., 1999 (Richardson et al., , 2002 . Furthermore, to our knowledge the siRNA constructs that utilize the 2 0 -F modified nucleosides have been negative in genetic toxicity studies, although there are limited primary references from which to draw (Berman et al., 2016; Janas et al., 2016) . In contrast to the more metabolically labile siRNA, single stranded antisense oligonucleotides are usually designed with phosphorothioate backbone linkages throughout the molecule with the modified nucleotides at terminal ends (eg, 2 0 -O-MOE)
providing further nuclease resistance (Bennett and Swayze, 2010) . Therefore, the nucleoside concentrations used in this in vitro study are unlikely to be achieved following in vivo administration due to the slow degradation of oligonucleotides (Watanabe et al., 2006) . Ultimately, the 2'-O-MOE modified wings are largely excreted in urine with limited degradation of the modified nucleotides (Geary et al., 2001b) . Although they are not incorporated into DNA and RNA, 2 0 -O-MOE nucleosides could exert mutagenic consequences via a mechanism other than direct DNA incorporation such as nucleotide pool balance disruption although this potential mechanism is unlikely given the lack of phosphorylation, the slow rate of metabolism and the consistent lack of genotoxicity that has been reported (Berman et al., 2016; Henry et al., 2002) . The utility of nonnatural 2 0 -sugar modification in oligonucleotide-based gene silencing technologies has proven valuable for their clinical development. These 2 0 -sugar modifications confer an RNA-like C3 0 -endo conformation which enhances the binding affinity to the target RNA . The chemical structure of 2 0 -O-MOE and 2 0 -F nucleosides analogous closely mimics the natural nucleosides where the nucleobase component is unmodified. It is possible that the reduced steric interactions of the less bulky fluorine atom combined with its higher hydrophobicity is likely responsible for the higher ability of kinase salvage enzymes and cellular polymerases to accept 2 0 -F nucleoside analog as a substrate resulting in their incorporation into genomic DNA. Further understanding of structure-activity relationship will help in the design of novel chemical modifications at the 2 0 -postion of the sugar moiety with improved chemical and biological stability.
In conclusion, we found that 2 0 -O-MOE nucleoside analogs are poor substrates for salvage enzymes largely preventing the formation of their corresponding active 5 0 -triphosphates and subsequent incorporation into cellular DNA and RNA. To our knowledge, this is the first study exploring the phosphorylation and DNA incorporation of 2 0 -O-MOE modified nucleotides. It is clear from this study that there is a link between the substrate specificity of nucleotide salvage enzymes towards 2 0 -sugar modified nucleoside analogs and cellular DNA incorporation. We believe the current work provides insight for the design of nucleoside analogs with higher activity and improved safety profile when incorporated into therapeutic oligonucleotides.
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